In in vitro and in vivo test results published January 25 in Science, ADG2 was found to bind to all known variants of SARS-CoV-2 and a range of sarbecoviruses that pose a threat to humans, according to the company. Additionally, ADG2 yielded protective efficacy in mouse models of SARS and COVID-19 and offered similar or higher potency against SARS-CoV-2 compared with other monoclonal antibodies in development or approved for emergency use, Adagio said.

Adagio said that ADG20 -- its half-life engineered version of ADG2 -- could offer protection against COVID-19 for up to a year. ADG20 is expected to enter phase I clinical studies in early 2021.

2003 SARS-CoV antibodies may provide some protection from SARS-CoV-2
A new study shows that antibodies against the original 2003 SARS-CoV also react with the current SARS-CoV-2 strain, but only with limited effectiveness....

Can antibodies to seasonal coronaviruses protect against SARS-CoV-2?
COVID-19 is not the world's first exposure to a coronavirus. With at least six previous exposures to various types of coronaviruses, researchers are exploring...

New study finds SARS-CoV-2 antibodies disappear quickly
Antibodies that develop after infection with the SARS-CoV-2 virus disappear quickly, according to an analysis published in Science Immunology...

New evidence shows SARS-CoV-2 mutations are not more transmissible
In direct contrast to previous research, researchers found that SARS-CoV-2 mutations are not tied to increased transmissibility in humans. The findings,...